Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model

BackgroundNatural history models of human papillomavirus (HPV) infection and disease have been used in a number of policy evaluations of technologies to prevent and screen for HPV disease (e.g., cervical cancer, anogenital warts), sometimes with wide variation in values for epidemiologic and clinical inputs. The objectives of this study are to: (1) Provide an updated critical and systematic review of the evidence base to support epidemiologic and clinical modeling of key HPV disease-related parameters in the context of an HPV multi-type disease transmission model which we have applied within a U.S. population context; (2) Identify areas where additional studies are particularly needed.MethodsConsistent with our and other prior HPV natural history models, the literature review was confined to cervical disease and genital warts. Between October 2005 and January 2006, data were gathered from the published English language medical literature through a search of the PubMed database and references were examined from prior HPV natural history models and review papers. Study design and data quality from individual studies were compared and analyses meeting pre-defined criteria were selected.ResultsPublished data meeting review eligibility criteria were most plentiful for natural history parameters relating to the progression and regression of cervical intraepithelial neoplasia (CIN) without HPV typing, and data concerning the natural history of HPV disease due to specific HPV types were often lacking. Epidemiologic evidence to support age-dependency in the risk of progression and regression of HPV disease was found to be weak, and an alternative hypothesis concerning the time-dependence of transition rates is explored. No data were found on the duration of immunity following HPV infection. In the area of clinical management, data were observed to be lacking on the proportion of clinically manifest anogenital warts that are treated and the proportion of cervical cancer cases that become symptomatic by stage.ConclusionKnowledge of the natural history of HPV disease has been considerably enhanced over the past two decades, through the publication of an increasing number of relevant studies. However, considerable opportunity remains for advancing our understanding of HPV natural history and the quality of associated models, particularly with respect to examining HPV age- and type-specific outcomes, and acquired immunity following infection.

[1]  G. Gildengorin,et al.  Current cervical neoplasia screening practices of obstetrician/gynecologists in the US. , 2005, American journal of obstetrics and gynecology.

[2]  M. Weinstein,et al.  A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine , 2003, International journal of cancer.

[3]  C. Wheeler,et al.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.

[4]  S. Collins,et al.  A critique of cohort studies examining the role of human papillomavirus infection in cervical neoplasia , 2002, BJOG : an international journal of obstetrics and gynaecology.

[5]  S. Wacholder,et al.  Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.

[6]  Lydia P. Howell,et al.  NATURAL HISTORY OF CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS: A META‐ANALYSIS , 1998, Obstetrics and gynecology.

[7]  M. Nygård,et al.  Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program , 2005, Cancer Causes & Control.

[8]  K. Holmes,et al.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection , 1992, The New England journal of medicine.

[9]  T. Iannicelli,et al.  Intramuscular interferon‐β treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection , 1994 .

[10]  S. Ebrahim,et al.  Use of cervical cancer screening among insured women: the extent of missed opportunities. , 2005, Health policy.

[11]  Milton C Weinstein,et al.  Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. , 2004, Journal of the National Cancer Institute.

[12]  N. Lurie,et al.  Accuracy of self-report of mammography and Pap smear in a low-income urban population. , 1998, American journal of preventive medicine.

[13]  J. Fowles,et al.  Comparing Claims Data and Self-Reported Data with the Medical Record for Pap Smear Rates , 1997, Evaluation & the health professions.

[14]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[15]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[16]  J. Berkhof,et al.  Natural history and screening model for high‐risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands , 2005, International journal of cancer.

[17]  J. Doorbar,et al.  Human Papillomaviruses , 2006, Methods in Molecular Medicine.

[18]  A. As A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. , 1997, British journal of obstetrics and gynaecology.

[19]  H. Dorn,et al.  Morbidity from cancer in the United States. , 1953, Acta - Unio Internationalis Contra Cancrum.

[20]  Y. Taketani,et al.  IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia. , 2006, Cancer letters.

[21]  D. A. Goldman,et al.  Validity of Pap smear and mammogram self-reports in a low-income Hispanic population. , 1995, American journal of preventive medicine.

[22]  L. Billingham,et al.  The effect of directed biopsy on the atypical cervical transformation zone: assessed by digital imaging colposcopy , 1996, British journal of obstetrics and gynaecology.

[23]  Erik J. Dasbach,et al.  Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.

[24]  J. Fortenberry,et al.  A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. , 2005, The Journal of infectious diseases.

[25]  A. Friedman-kien Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived). , 1995, American journal of obstetrics and gynecology.

[26]  Heather Langhan Medical Student,et al.  A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia , 2005 .

[27]  K. Yamato,et al.  Eradication of HPV post-surgical treatments, its correlation with specific types, types of surgery and the physical status. , 2004, Oncology reports.

[28]  P. Porter,et al.  Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. , 2001, Cancer research.

[29]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[30]  J. Meigs,et al.  Uterine cervical carcinoma in Connecticut, 1935-1973: evidence for two classes of invasive disease. , 1976, Journal of the National Cancer Institute.

[31]  Homa Keshavarz,et al.  Hysterectomy surveillance -- United States 1994-1999. , 2002 .

[32]  Philippe Vielh,et al.  Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening , 2003, BMJ : British Medical Journal.

[33]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[34]  R. Hiatt,et al.  Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan , 2000, Journal of lower genital tract disease.

[35]  B. Olgemöller,et al.  Type-Specific Detection of Human Papillomaviruses in a Routine Laboratory Setting – Improved Sensitivity and Specificity of PCR and Sequence Analysis Compared to Direct Hybridisation , 2003, Clinical chemistry and laboratory medicine.

[36]  D. Towsend Persistent intraepithelial neoplasia after excision for cervical intraepithelial neoplasia grade III. , 1997, Obstetrics and gynecology.

[37]  M. Plummer,et al.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.

[38]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[39]  J. Holmes,et al.  The cost-effectiveness of human papillomavirus screening for cervical cancer , 2005, The European Journal of Health Economics.

[40]  I. Merkatz,et al.  Clinical Usefulness of Computerized Colposcopy: Image Analysis and Conservative Management of Mild Dysplasia , 1992, Obstetrics and gynecology.

[41]  D. Jeffe,et al.  Effect of area poverty rate on cancer screening across US communities , 2006, Journal of Epidemiology and Community Health.

[42]  M. Fahs,et al.  Cost Effectiveness of Cervical Cancer Screening for the Elderly , 1992, Annals of Internal Medicine.

[43]  R. Hiatt,et al.  Concordance of self-reported data and medical record audit for six cancer screening procedures. , 1993, Journal of the National Cancer Institute.

[44]  G. Bigras,et al.  The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13 842 women , 2005, British Journal of Cancer.

[45]  A. Östör,et al.  Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International Journal of Gynecological Pathology.

[46]  I. I. Kessler Cervical cancer epidemiology in historical perspective. , 1974, The Journal of reproductive medicine.

[47]  Guoyu Tao,et al.  The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. , 2004, Perspectives on sexual and reproductive health.

[48]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[49]  Scott B. Cantor,et al.  COLPOSCOPY FOR THE DIAGNOSIS OF SQUAMOUS INTRAEPITHELIAL LESIONS: A META‐ANALYSIS , 1998, Obstetrics and gynecology.

[50]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[51]  A. Giuliano,et al.  Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. , 2002, The Journal of infectious diseases.

[52]  S Sudman,et al.  Cognitive aspects of recalling and reporting health-related events: Papanicolaou smears, clinical breast examinations, and mammograms. , 1997, American journal of epidemiology.

[53]  Shalini L Kulasingam,et al.  Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. , 2002, JAMA.

[54]  C. Redman,et al.  Loop diathermy excision of the cervical transformation zone in patients with abnormal cervical smears. , 1990, BMJ.

[55]  A. Moscicki,et al.  External genital warts: diagnosis, treatment, and prevention. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  M. Sherman,et al.  Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection , 2004, Cancer Epidemiology Biomarkers & Prevention.

[57]  M. Lehtinen,et al.  Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses , 2006, PLoS medicine.

[58]  A. Teyssié,et al.  Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision. , 1998, Infectious diseases in obstetrics and gynecology.

[59]  M. Plummer,et al.  Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. , 2003, American journal of epidemiology.

[60]  Michal Abrahamowicz,et al.  The natural history of type-specific human papillomavirus infections in female university students. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[61]  S. Syrjänen,et al.  Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union , 2005, International journal of STD & AIDS.

[62]  E. Dasbach,et al.  Incidence and Duration of Cervical Human Papillomavirus 6, 11, 16, and 18 Infections in Young Women: An Evaluation from Multiple Analytic Perspectives , 2007, Cancer Epidemiology Biomarkers & Prevention.

[63]  M. von Knebel Doeberitz,et al.  Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. , 1999, Journal of clinical pathology.

[64]  E. Dasbach,et al.  Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women , 2007, Infectious Agents and Cancer.

[65]  C. Woodman,et al.  Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study , 2001, The Lancet.

[66]  Nancy Breen,et al.  Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey. , 2004, Preventive medicine.

[67]  A. Glass,et al.  Diagnoses and outcomes in cervical cancer screening: a population-based study. , 2004, American journal of obstetrics and gynecology.

[68]  K. Syrjänen,et al.  Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). , 1996, European journal of obstetrics, gynecology, and reproductive biology.

[69]  V Beral,et al.  The predicted effect of changes in cervical screening practice in the UK: results from a modelling study , 2004, British Journal of Cancer.

[70]  B. Quade,et al.  In vivo cyclin E expression as a marker for early cervical neoplasia. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[71]  C. Callahan,et al.  Accuracy of self-reported health services use and patterns of care among urban older adults. , 1999, Medical care.

[72]  C. Woodman,et al.  Human papillomavirus infection and risk of progression of epithelial abnormalities of the cervix. , 1996, British Journal of Cancer.

[73]  Elamin H Elbasha,et al.  Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. , 2006, Epidemiologic reviews.

[74]  T. Wright,et al.  Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. , 2002, JAMA.

[75]  M. Schiffman,et al.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. , 2001, Journal of the National Cancer Institute.

[76]  O. Ahmadpour,et al.  Management of Female Genital Warts with an Analog of Imiquimod 2% in Cream: A Randomized, Double‐Blind, Placebo‐Controlled Study , 1998, The Journal of dermatology.

[77]  J. Coste,et al.  Cost‐effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: Protocol of the study of the French Society of Clinical Cytology , 2001, Diagnostic cytopathology.

[78]  Calum MacAulay,et al.  Natural History of Cervical Intraepithelial Neoplasia , 2005, Acta Cytologica.

[79]  J. Redburn,et al.  Hysterectomy prevalence and adjusted cervical and uterine cancer rates in England and Wales , 2001, BJOG : an international journal of obstetrics and gynaecology.

[80]  K. Cooper,et al.  Biotinyl-Tyramide-Based In Situ Hybridization Signal Patterns Distinguish Human Papillomavirus Type and Grade of Cervical Intraepithelial Neoplasia , 2002, Modern Pathology.

[81]  H. Ngan,et al.  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[82]  H. Shimada,et al.  Uterine Cervical Dysplasia and Cancer: Identification of C-myc Status by Quantitative Polymerase Chain Reaction , 1998, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[83]  L. Smart,et al.  Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia , 2002, BJOG : an international journal of obstetrics and gynaecology.

[84]  Johannes Haerting,et al.  Screening for high‐grade cervical intra‐epithelial neoplasia and cancer by testing for high‐risk HPV, routine cytology or colposcopy , 2000, International journal of cancer.

[85]  W. Lawrence,et al.  Benefits and costs of using HPV testing to screen for cervical cancer. , 2002, JAMA.

[86]  S. Quah,et al.  Patient assessment of anogenital warts and the success of treatment with home applied therapy. , 2004, International journal of STD & AIDS.

[87]  M. Stoler,et al.  Detection of Multiple Human Papillomavirus Types in Condylomata Acuminata Lesions from Otherwise Healthy and Immunosuppressed Patients , 1999, Journal of Clinical Microbiology.

[88]  G. Nuovo,et al.  Human Papillomavirus Detection in Cervical Lesions Nondiagnostic for Cervical Intraepithelial Neoplasia: Correlation With Papanicolaou Smear, Colposcopy, and Occurrence of Cervical Intraepithelial Neoplasia , 1990, Obstetrics and Gynecology.

[89]  C. Wheeler,et al.  Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.

[90]  Gillian D. Sanders,et al.  Cost Effectiveness of a Potential Vaccine for Human papillomavirus , 2003, Emerging infectious diseases.

[91]  A. Glass,et al.  Response to "Use of cervical cancer screening among insured women: the extent of missed opportunities" [Health Policy 73 (2005) 194-201]. , 2006, Health policy.

[92]  Adalsteinn D. Brown,et al.  Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. , 1999, JAMA.

[93]  D T Janerich,et al.  The screening histories of women with invasive cervical cancer, Connecticut. , 1995, American journal of public health.

[94]  L. Koss,et al.  Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. , 2003, Human pathology.

[95]  V. Kataja,et al.  Prevalence of Genital Human Papillomavirus Infections in a Mass-Screened Finnish Female Population Aged 20–65 Years , 1990, International journal of STD & AIDS.

[96]  P. de Cremoux,et al.  Regression of Low-Grade Cervical Intraepithelial Neoplasia in Patients With HLA-DRB1*13 Genotype , 2004, Obstetrics and gynecology.

[97]  B. Goff,et al.  Large loop excision of the transformation zone in patients with exocervical squamous intraepithelial lesions. , 1994, European journal of gynaecological oncology.

[98]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[99]  N. Kiviat,et al.  Development and duration of human papillomavirus lesions, after initial infection. , 2005, The Journal of infectious diseases.

[100]  P. Martin-Hirsch,et al.  The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. , 2004, Cancer treatment reviews.

[101]  L. Stanberry,et al.  Preface to the fifth edition , 2014 .

[102]  J. Simpson,et al.  Progression and Regression of Low‐grade Epithelial Abnormalities of the Cervix , 1997, The Australian & New Zealand journal of obstetrics & gynaecology.

[103]  Kathleen R. Cho,et al.  Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. , 1996, Cancer research.

[104]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[105]  S. Chow,et al.  Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. , 1999, Gynecologic oncology.

[106]  Shalini L Kulasingam,et al.  Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. , 2003, JAMA.

[107]  C. Wheeler,et al.  Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts , 1995, Journal of clinical microbiology.

[108]  R. Sanson-Fisher,et al.  Accuracy of patients' recall of pap and cholesterol screening. , 2001, Journal of lower genital tract disease.

[109]  S. Tyring,et al.  Genital warts and their treatment. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[110]  W. Quint,et al.  The role of genotype‐specific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia , 2002, International journal of cancer.

[111]  R. Detels,et al.  Validity of self-reporting of episodes of external genital warts. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[112]  M. Kosinski,et al.  GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side , 2007, Clinical pharmacology and therapeutics.

[113]  D C McCrory,et al.  Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. , 2000, American journal of epidemiology.

[114]  G. Lovelace,et al.  Detection of human papillomavirus DNA by in situ hybridization and polymerase chain reaction in human papillomavirus equivocal and dysplastic cervical biopsies. , 1993, Human pathology.

[115]  E. Lazcano-Ponce,et al.  Prognostic factors related to cervical cancer survival in Mexican women , 2001, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[116]  M. Lehtinen,et al.  Stability over time of serum antibody levels to human papillomavirus type 16. , 1998, The Journal of infectious diseases.

[117]  B. Wiatrak Overview of recurrent respiratory papillomatosis , 2003, Current opinion in otolaryngology & head and neck surgery.

[118]  Helen Trottier,et al.  The epidemiology of genital human papillomavirus infection. , 2006, Vaccine.

[119]  J. Murdoch,et al.  Histological incomplete excision of CIN after large loop excision of the transformation zone (LLETZ) merits careful follow up, not retreatment , 1992, British journal of obstetrics and gynaecology.

[120]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[121]  H. Hoyer,et al.  Cumulative 5‐year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high‐risk HPV and cytology testing in a primary screening setting , 2005, International journal of cancer.

[122]  J. Salonen,et al.  Prospective follow-up of cervical HPV infections: Life table analysis of histopathological, cytological and colposcopic data , 1989, European Journal of Epidemiology.

[123]  T. Wright,et al.  Treatment of Cervical Intraepithelial Neoplasia Using the Loop Electrosurgical Excision Procedure , 1992, Obstetrics and gynecology.

[124]  I. Arany,et al.  Effect of Interferon Therapy on Human Papillomavirus Copy Number in Patients With Condyloma Acuminatum , 1995, American Journal of the Medical Sciences.

[125]  H. Welch,et al.  The frequency of Pap smear screening in the United States , 2004, Journal of General Internal Medicine.

[126]  L. Westergaard,et al.  Severe cervical dysplasia. Control by biopsies or primary conization? A comparative study. , 1982, Acta obstetricia et gynecologica Scandinavica.

[127]  A. Glass,et al.  Pap screening in a U.S. health plan. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[128]  S. Chow,et al.  Loop electrosurgical excision procedure for conization of the uterine cervix. , 1994, Journal of the Formosan Medical Association = Taiwan yi zhi.